Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · Chief Executive Officer | May 29, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 290,687 |
Last balance in matching sequence
After 2019-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-29 · Sale · Disposed 2,200 · Balance 294,337 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 2 · 2019-05-29 · Sale · Disposed 725 · Balance 293,612 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 3 · 2019-05-30 · Sale · Disposed 1,425 · Balance 292,187 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 4 · 2019-05-30 · Sale · Disposed 1,500 · Balance 290,687 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 332,243 |
Reported balance
Holding disclosure · report date 2019-05-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 332,243 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2019 Filed May 31, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $23.70 | $35,550.00 |
DisclosureSEC source: 0001209191-19-033638 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 290,687 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 30, 2019 Filed May 31, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,425 | $22.72 | $32,376.00 |
DisclosureSEC source: 0001209191-19-033638 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 292,187 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 725 | $23.30 | $16,892.50 |
DisclosureSEC source: 0001209191-19-033638 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 293,612 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $22.85 | $50,270.00 |
DisclosureSEC source: 0001209191-19-033638 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 294,337 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 14, 2019 Filed May 15, 2019 16:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $24.92 | $97,188.00 |
DisclosureSEC source: 0001209191-19-030024 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 296,537 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $24.51 to $25.08. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 400 | $24.95 | $9,980.00 |
DisclosureSEC source: 0001209191-19-030024 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 300,437 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $24.91 to $25.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $24.23 | $84,805.00 |
DisclosureSEC source: 0001209191-19-030024 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 300,837 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.75 to $24.62. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $33.47 | $130,533.00 |
DisclosureSEC source: 0001209191-19-026446 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 304,337 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.11 to $33.935. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $33.99 | $10,197.00 |
DisclosureSEC source: 0001209191-19-026446 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 308,237 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.98 to $34.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $33.57 | $120,852.00 |
DisclosureSEC source: 0001209191-19-026446 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 308,537 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.97 to $33.865. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $36.27 | $141,453.00 |
DisclosureSEC source: 0001209191-19-024482 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 312,137 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $36.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $37.04 | $144,456.00 |
DisclosureSEC source: 0001209191-19-024482 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 316,037 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.74 to $37.48. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $41.70 | $8,340.00 |
DisclosureSEC source: 0001209191-19-021972 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 319,937 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.695 to $41.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,700 | $39.81 | $147,297.00 |
DisclosureSEC source: 0001209191-19-021972 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 320,137 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.50 to $40.375. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $38.59 | $11,577.00 |
DisclosureSEC source: 0001209191-19-021972 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 323,837 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.53 to $38.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,600 | $38.02 | $60,832.00 |
DisclosureSEC source: 0001209191-19-021972 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 324,137 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.50 to $38.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 16:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $36.75 | $73,500.00 |
DisclosureSEC source: 0001209191-19-021972 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 325,737 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.30 to $37.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 16:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $38.73 | $151,047.00 |
DisclosureSEC source: 0001209191-19-019979 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 327,737 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.15 to $39.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 16:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,200 | $40.48 | $129,536.00 |
DisclosureSEC source: 0001209191-19-019979 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 331,637 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.02 to $40.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 16:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 700 | $39.10 | $27,370.00 |
DisclosureSEC source: 0001209191-19-019979 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 334,837 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.92 to $39.39. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 16:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $36.13 | $140,907.00 |
DisclosureSEC source: 0001209191-19-014944 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 335,537 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.80 to $36.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,700 | $36.20 | $133,940.00 |
DisclosureSEC source: 0001209191-19-014944 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 339,437 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.98 to $36.46. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 200 | $35.22 | $7,044.00 |
DisclosureSEC source: 0001209191-19-014944 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 343,137 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.87 to $35.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 17:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 1,176 | $40.45 | $47,569.20 |
DisclosureSEC source: 0001209191-19-011179 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,243 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $39.01 | $152,139.00 |
DisclosureSEC source: 0001209191-19-009508 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 342,138 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.75 to $39.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $38.52 | $150,228.00 |
DisclosureSEC source: 0001209191-19-009508 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 346,038 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.12 to $39.07. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| February 09, 2019 Filed Feb 12, 2019 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 20,324 | $38.49 | $782,270.76 |
DisclosureSEC source: 0001209191-19-009508 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,618 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 24,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008521 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,611 F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2019 Filed Feb 12, 2019 19:17 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 24,683 | $38.47 | $949,555.01 |
DisclosureSEC source: 0001209191-19-009507 · doc4a.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,611 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. F2 · price: Filed solely to state the price which was inadvertently omitted. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 430 | $35.82 | $15,402.60 |
DisclosureSEC source: 0001209191-19-005448 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 296,452 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.635 to $36.07. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,470 | $34.98 | $121,380.60 |
DisclosureSEC source: 0001209191-19-005448 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 296,882 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.50 to $35.49. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $36.58 | $3,658.00 |
DisclosureSEC source: 0001209191-19-005448 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 300,352 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 800 | $35.59 | $28,472.00 |
DisclosureSEC source: 0001209191-19-005448 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 300,452 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.40 to $36.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,000 | $34.84 | $104,520.00 |
DisclosureSEC source: 0001209191-19-005448 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 301,252 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.35 to $35.12. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 18:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $34.50 | $75,900.00 |
DisclosureSEC source: 0001209191-19-003315 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.38 to $34.68. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 18:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,700 | $33.93 | $57,681.00 |
DisclosureSEC source: 0001209191-19-003315 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.36 to $34.36. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 18:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-19-003315 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.99 to $35.43. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 18:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,900 | $34.51 | $65,569.00 |
DisclosureSEC source: 0001209191-19-003315 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.97 to $34.905. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2018 Filed Dec 28, 2018 18:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $35.40 | $17,700.00 |
DisclosureSEC source: 0001209191-18-064352 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.14 to $35.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2018 Filed Dec 28, 2018 18:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,400 | $34.60 | $117,640.00 |
DisclosureSEC source: 0001209191-18-064352 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.13 to $35.12. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 18:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 653 | $34.19 | $22,326.07 |
DisclosureSEC source: 0001209191-18-064352 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.05 to $34.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 18:51 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,247 | $32.82 | $106,566.54 |
DisclosureSEC source: 0001209191-18-064352 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 16,431 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.48 to $33.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 18:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $42.75 | $166,725.00 |
DisclosureSEC source: 0001209191-18-062527 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.48 to $42.96. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 18:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $42.56 | $165,984.00 |
DisclosureSEC source: 0001209191-18-062527 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.17 to $43.16. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 29, 2018 Filed Nov 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $42.26 | $105,650.00 |
DisclosureSEC source: 0001209191-18-060311 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 27,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.68 to $42.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 29, 2018 Filed Nov 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,400 | $41.13 | $57,582.00 |
DisclosureSEC source: 0001209191-18-060311 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 29,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.65 to $41.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,200 | $39.54 | $47,448.00 |
DisclosureSEC source: 0001209191-18-060311 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.705. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,700 | $38.65 | $104,355.00 |
DisclosureSEC source: 0001209191-18-060311 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 32,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.14 to $39.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 19:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,800 | $35.49 | $99,372.00 |
DisclosureSEC source: 0001209191-18-058820 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.11 to $35.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 19:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $34.67 | $38,137.00 |
DisclosureSEC source: 0001209191-18-058820 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.07 to $35.07. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.